Zobrazeno 1 - 10 of 271 pro vyhledávání: '"Glenwood D Goss"'
1
Akademický článek
Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic
Autor: Glenwood D. Goss, Johanna N. Spaans, David Huntsman, Timothy Asmis, Natalie M. Andrews Wright, Marc Duciaume, Pardeep Kaurah, Ruth R. Miller, Shantanu Banerji, Harmanjatinder S. Sekhon, Marcio M. Gomes
Publikováno v: Current Oncology, Vol 29, Iss 5, Pp 3171-3186 (2022)
Inuit are the Indigenous Arctic peoples and residents of the Canadian territory of Nunavut who have the highest global rate of lung cancer. Given lung cancer’s mortality, histological and genomic characterization was undertaken to better understand
Externí odkaz: https://doaj.org/article/19fa4df936c2416ab987aef3528518a4
Zobrazit plný text záznamu
2
Akademický článek
Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first‐line platinum chemotherapy in high grade serous ovarian cancer
Autor: Johanne I. Weberpals, Trevor J. Pugh, Paola Marco‐Casanova, Glenwood D. Goss, Natalie Andrews Wright, Prisni Rath, Jonathon Torchia, Alexander Fortuna, Gemma N. Jones, Martine P. Roudier, Laurence Bernard, Bryan Lo, Dax Torti, Alberto Leon, Kayla Marsh, Darren Hodgson, Marc Duciaume, William J. Howat, Natalia Lukashchuk, Stanley E. Lazic, Doreen Whelan, Harmanjatinder S. Sekhon
Publikováno v: Cancer Medicine, Vol 10, Iss 9, Pp 3045-3058 (2021)
Abstract Background In high grade serous ovarian cancer (HGSOC), there is a spectrum of sensitivity to first line platinum‐based chemotherapy. This study molecularly characterizes HGSOC patients from two distinct groups of chemotherapy responders (
Externí odkaz: https://doaj.org/article/8826b110dfd043bcab07785ab9fa87ae
Zobrazit plný text záznamu
3
Akademický článek
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial
Autor: Glenwood D. Goss, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Dolores Isla, Alessandro Morabito, Young J. Min, Andrea Ardizzoni, Shaun Bender, Agnieszka Cseh, Enriqueta Felip
Publikováno v: EClinicalMedicine, Vol 37, Iss , Pp 100940- (2021)
Background: LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung. We report the final overall survival (OS) and safety ana
Externí odkaz: https://doaj.org/article/d8fe0d7fea454b01b8c9f6bcd8ec32f9
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje